136 related articles for article (PubMed ID: 11675134)
21. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
[TBL] [Abstract][Full Text] [Related]
22. Genetic parameters of neuroblastomas.
Westermann F; Schwab M
Cancer Lett; 2002 Oct; 184(2):127-47. PubMed ID: 12127685
[TBL] [Abstract][Full Text] [Related]
23. Amplification of the MYCN oncogene and deletion of putative tumour suppressor gene in human neuroblastomas.
Schwab M
Brain Pathol; 1990 Sep; 1(1):41-6. PubMed ID: 1669692
[TBL] [Abstract][Full Text] [Related]
24. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines.
Van Roy N; Laureys G; Cheng NC; Willem P; Opdenakker G; Versteeg R; Speleman F
Genes Chromosomes Cancer; 1994 Jun; 10(2):103-14. PubMed ID: 7520263
[TBL] [Abstract][Full Text] [Related]
25. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
[TBL] [Abstract][Full Text] [Related]
26. [The neuroblastoma, "enfant terrible" among pediatric tumors].
Laureys G
Verh K Acad Geneeskd Belg; 2003; 65(1):5-23; discussion 23-8. PubMed ID: 12802894
[TBL] [Abstract][Full Text] [Related]
27. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
[TBL] [Abstract][Full Text] [Related]
28. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
[TBL] [Abstract][Full Text] [Related]
29. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
30. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
31. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
[TBL] [Abstract][Full Text] [Related]
32. Full cytogenetic characterization of a new neuroblastoma cell line with a complex 17q translocation.
Panarello C; Morerio C; Russo I; Pasquali F; Rapella A; Corrias MV; Morando A; Rosanda C
Cancer Genet Cytogenet; 2000 Jan; 116(2):124-32. PubMed ID: 10640144
[TBL] [Abstract][Full Text] [Related]
33. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
34. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
35. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.
Lastowska M; Cotterill S; Pearson AD; Roberts P; McGuckin A; Lewis I; Bown N
Eur J Cancer; 1997 Sep; 33(10):1627-33. PubMed ID: 9389925
[TBL] [Abstract][Full Text] [Related]
36. Neuroblastoma--clinical applications of molecular parameters.
Brodeur GM
Brain Pathol; 1990 Sep; 1(1):47-54. PubMed ID: 1669693
[TBL] [Abstract][Full Text] [Related]
37. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
38. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.
Corvi R; Savelyeva L; Breit S; Wenzel A; Handgretinger R; Barak J; Oren M; Amler L; Schwab M
Oncogene; 1995 Mar; 10(6):1081-6. PubMed ID: 7700632
[TBL] [Abstract][Full Text] [Related]
39. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.
Lastowska M; Cullinane C; Variend S; Cotterill S; Bown N; O'Neill S; Mazzocco K; Roberts P; Nicholson J; Ellershaw C; Pearson AD; Jackson MS;
J Clin Oncol; 2001 Jun; 19(12):3080-90. PubMed ID: 11408505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
